CTOs on the Move


 
Axsome Therapeutics is a biopharmaceutical company developing novel therapies for the treatment of CNS disorders. Axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. The company is based in New York City.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.axsome.com
  • 200 Broadway 3rd Floor
    New York, NY USA 10004
  • Phone: 212.332.3241

Executives

Name Title Contact Details
Mark Jacobson
Chief Operating Officer Profile

Funding

Axsome raised $200M on 12/23/2019

Similar Companies

Cogenix

Cogenix is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Percivia

Percivia is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ludesi

Ludesi is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Molecular Express

Molecular Express is a Rancho Dominguez, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allakos

Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company`s lead antibody, lirentelimab (AK002), is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study in eosinophilic esophagitis (EoE). Lirentelimab targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Lirentelimab has been tested in multiple clinical studies. In these studies, lirentelimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with EG and/or EoD, EoE, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria and indolent systemic mastocytosis.